Aberrantly expressing CD4 positive nodular sclerosis subtype classical Hodgkin lymphoma patients at baseline may be candidates for frontline brentuximab vedotin administration, if verified in large clinical trials. Here, CD4 is linked to Hodgkins lymphoma.